HDAC inhibitor DWP0016 activates p53 transcription and acetylation to inhibit cell growth in U251 glioblastoma cells

Journal of Cellular Biochemistry

Volumn 114, Issue 7, 2013, Pages 1498-1509

  Jin, Hui ^a   Liang, Lei ^a   Liu, Lifeng ^a   Deng, Weiping ^a   Liu, Jianwen ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

ACETYL p53; APOPTOSIS; CYCLE ARREST; HDAC INHIBITOR; p53

Indexed keywords

3 (2 BENZYL 5 (2 (PIPERIDIN 1 YL)ETHYL) 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B])INDOL 8 YL N HYDROXYACRYLAMIDE; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D; CYCLIN E; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CATALYSIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ACETYLATION; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOPRECIPITATION; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877703403     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24491     Document Type: Article

References (66)

1. Acharya M, Sparreboom A, Venitz J, Figg W,. 2005. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68: 917.
2. Adams J, Cory S,. 2007. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324.
3. Bajbouj K, Mawrin C, Hartig R, Schulze-Luehrmann J, Wilisch-Neumann A, Roessner A, Schneider-Stock R,. 2012. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J Neurooncol 107 (3): 503-516.
4. Balasubramanian S, Verner E, Buggy JJ,. 2009. Isoform-specific histone deacetylase inhibitors: The next step ? Cancer Lett 280: 211-221.
5. Baylin S, Ohm J,. 2006. Epigenetic gene silencing in cancer-A mechanism for early oncogenic pathway addiction ? Nat Rev Cancer 6: 107-116. (Pubitemid 43361543)
6. Bolden J, Peart M, Johnstone R,. 2006. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. (Pubitemid 44348499)
7. Brosh R, Rotter V,. 2009. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer. 9 (10): 701-713.
8. Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ,. 2005. Influence of in vivo growth on human glioma cell line gene expression: Convergent profiles under orthotopic conditions. Proc Natl Acad Sci USA 102: 8287-8292. (Pubitemid 40800081)
9. Candolfi M, Curtin JF, Nichols WS, Muhammad AKMG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF,. 2007. Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression. J Neurooncol 85: 133-148. (Pubitemid 47629395)
10. Chen C, Weng S, Tseng P, Lin H,. 2005. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879.
11. Chiang M-F, Yeh S-T, Liao H-F, Chang N-S, Chen Y-J,. 2012. Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. Biomed Pharmacother 66: 433-438.
12. Choudhary C, Kumar C, Gnad F, Nielsen M, Rehman M, Walther T, Olsen J, Mann M,. 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 14;325 (5942): 834-840.
13. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ,. 1993. Gain of function mutations in p53. Nat Genet 4: 42-46. (Pubitemid 23165910)
14. Drummond D, Noble C, Kirpotin D, Guo Z, Scott G, Benz C,. 2005. Clinical development of histone deacetylase inhibitors as anticancer agents. Pharmacol Toxicol 45: 495.
15. Edwards L, Thiessen B, Dragowska W, Daynard T, Bally M, Dedhar S,. 2005. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 24: 3596-3605. (Pubitemid 40756229)
16. Egger G, Liang G, Aparicio A, Jones P,. 2004. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463. (Pubitemid 38715140)
17. Eyülpoglu IY, Hahnen E, Buslei R, Siebzehnrülbl FA, Savaskan NE, Lülders M, Trnkle C, Wick W, Weller M, Fahlbusch R,. 2005. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93 (4): 992-999. (Pubitemid 40695758)
18. Fournel M, Bonfils C, Hou Y, Yan P, Trachy-Bourget M, Kalita A, Liu J, Lu A, Zhou N, Robert M,. 2008. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7: 759.
19. Frazier MW, He X, Wang JL, Gu Z, Cleveland JL, Zambetti GP,. 1998. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 18: 3735-3743. (Pubitemid 28287895)
20. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C,. 2007. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Develop 21: 2683.
21. Gan Y, Wang J, Coselli J, Wang X,. 2008. Synergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cells. Biochem Biophys Res Commun 365: 386-392. (Pubitemid 350148074)
22. Gray S, Ekstrm T,. 2001. The human histone deacetylase family. Exp Cell Res 262: 75-83. (Pubitemid 32980246)
23. Grzmil M, Morin P, Lino MM, Merlo A, Frank S, Wang Y, Moncayo G, Hemmings BA,. 2011. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. Cancer Res 71 (6): 2392-2402.
24. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP,. 2000. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2: 730-736.
25. Hamada K, Sasaki T, Koni P, Natsui M, Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M,. 2005. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Develop 19: 2054.
26. Hastak K, Agarwal MK, Mukhtar H, Agarwal ML,. 2005. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 19: 789.
27. Hoyer D, Clarke DE, Fozard JR, Hartig P, Martin GR, Mylecharane EJ, Saxena PR, Humphrey P,. 1994. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46: 157-203. (Pubitemid 24185150)
28. Hoyer D, Hannon JP, Martin GR,. 2002. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554. (Pubitemid 34219205)
29. Hussain SP, Harris CC,. 1998. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58 (18): 4023-4037. (Pubitemid 28440548)
30. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP,. 2001. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20: 1331-1340. (Pubitemid 32233973)
31. Jeffers JR, Parganas E, Lee Y, Yang C, Wang JL, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN,. 2003. Puma is an essential mediator of p53-dependent and-independent apoptotic pathways. Cancer Cell 4: 321-328. (Pubitemid 37329796)
32. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y,. 2012. Antitumor activity of NVP-BKM120-A selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18: 184-195.
33. Kruse JP, Gu W,. 2009. Modes of p53 regulation. Cell 137: 609-622.
34. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP,. 2007. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121: 656-665. (Pubitemid 46986501)
35. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T,. 2002. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21: 2672-2681. (Pubitemid 34619383)
36. Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, Lee BL, Lee JS,. 2010. PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 18: 666-677.
37. Li Y, Mao Y, Brandt-Rauf P, Williams A, Fine R,. 2005. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther 4: 901.
38. Liang X, Xu Y, Xu K, Liu J, Qian X,. 2010. B1, a novel amonafide analogue, overcomes the resistance conferred by Bcl-2 in human promyelocytic leukemia HL60 cells. Mol Cancer Res 8: 1619.
39. Lin J, Teresky AK, Levine AJ,. 1995. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10: 2387.
40. Liu Y, Zhang S, Cai Y,. 2007. Cytoprotective effects of selenium on cadmium-induced LLC-PK1 cells apoptosis by activating JNK pathway. Toxicol In Vitro 21: 677-684. (Pubitemid 46550757)
41. Lu X, Liu DP, Xu Y,. 2012. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene. DOI: 10.1038/onc.2012.299 [Epub ahead of print].
42. Luo J, Su F, Chen D, Shiloh A, Gu W,. 2000. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381.
43. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK,. 2001. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1: 194-202. (Pubitemid 33741894)
44. Marks P, Miller T, Richon V,. 2003a. Histone deacetylases. Curr Opin Pharmacol 3: 344-351. (Pubitemid 36908937)
45. Marks PA, Miller T, Richon VM,. 2003b. Histone deacetylases. Curr Opin Pharmacol 3: 344-351. (Pubitemid 36908937)
46. Miyashita T, Reed J,. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293.
47. Nagarajan RP, Costello JF,. 2009. Epigenetic mechanisms in glioblastoma multiformeeditor, Elsevier, 19(3):188-197.
48. Nakano K, Vousden KH,. 2001. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694. (Pubitemid 32706359)
49. ©\ dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway. Cancer Sci 97: 430-436.
50. Qi S, Song Y, Peng Y, Wang H, Long H, Yu X, Li Z, Fang L, Wu A, Luo W,. 2012. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS ONE 7: e38842.
51. Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, Caprera F, Stortini G, Scanziani E, Pesenti E,. 2009. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol 24: 879.
52. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta G, Alcalay M, Seiser C,. 2007. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27: 4784.
53. Shinoura N, Muramatsu Y, Nishimura M, Yoshida Y, Saito A, Yokoyama T, Furukawa T, Horii A, Hashimoto M, Asai A,. 1999. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res 59: 5521-5528. (Pubitemid 29526468)
54. Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC,. 2010. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett 478: 165-170.
55. Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC,. 2010. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 18: 619-629.
56. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak T,. 2001. Regulation of PTEN transcription by p53. Mol Cell 8: 317-325. (Pubitemid 32831549)
57. Stegh AH, DePinho RA,. 2011. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell cycle (Georgetown, Tex.) 10.
58. Svejda B, Kidd M, Giovinazzo F, Eltawil K, Gustafsson BI, Pfragner R, Modlin IM,. 2010. The 5-HT2B receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer 116: 2902-2912.
59. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W,. 2008. Acetylation is indispensable for p53 activation. Cell 133: 612-626. (Pubitemid 351636297)
60. Ugur HC, Ramakrishna N, Bello L, Menon LG, Kim SK, Black PM, Carroll RS,. 2007. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 83: 267-275. (Pubitemid 46952237)
61. Vousden KH, Lane DP,. 2007. p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283. (Pubitemid 46474662)
62. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H,. 1997. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 523.
63. Yang X, Seto E,. 2007. HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26: 5310-5318. (Pubitemid 47255917)
64. Yu J, Zhang L,. 2008. PUMA, a potent killer with or without p53. Oncogene 27: S71-S83.
65. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q,. 2006. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21Waf1/Cip1. Mol Cell Biol 26: 2782.
66. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA,. 2001. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61: 1327.